Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Hutchison China Ads (HCM)

Hutchison China Ads (HCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,773,349
  • Shares Outstanding, K 133,381
  • Annual Sales, $ 214,110 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.47 +25.90%
on 01/27/20
29.92 -5.45%
on 01/21/20
-0.06 (-0.21%)
since 01/14/20
3-Month
22.19 +27.49%
on 12/17/19
29.92 -5.45%
on 01/21/20
+5.45 (+23.86%)
since 11/14/19
52-Week
16.47 +71.77%
on 09/30/19
32.55 -13.09%
on 04/10/19
+3.24 (+12.93%)
since 02/14/19

Most Recent Stories

More News
Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi(R) Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi (durvalumab) combination...

HCM : 28.29 (+1.40%)
Chi-Med Announces the Exercise of Underwriters' Over-allotment Option for Public Offering of ADSs

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

HCM : 28.29 (+1.40%)
Chi-Med to Announce 2019 Final Results

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2019 on Tuesday, March 3, 2020 at 7:00 am Greenwich Mean Time (GMT).

HCM : 28.29 (+1.40%)
Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

HCM : 28.29 (+1.40%)
Chi-Med Announces Proposed Public Offering of ADSs

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

HCM : 28.29 (+1.40%)
Moving Average Crossover Alert: Hutchison China MediTech

Hutchison China MediTech Limited (HCM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

HCM : 28.29 (+1.40%)
Will Hutchison China MediTech Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Hutchison China MediTech.

HCM : 28.29 (+1.40%)
Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee ("IDMC") of the Phase III pivotal study of surufatinib in advanced neuroendocrine...

HCM : 28.29 (+1.40%)
Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know

Does Hutchison China MediTech (HCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

HCM : 28.29 (+1.40%)
Neuroendocrine Carcinoma Market is projected to grow at a high 7.7% CAGR throughout 2017-2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 223.48 (+0.20%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.57 (+0.44%)
HCM : 28.29 (+1.40%)
LXRX : 2.90 (-3.33%)
NVS : 97.63 (-0.14%)
TEVA : 12.22 (-2.78%)
VRX.TO : 30.80 (-3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade HCM with:

Business Summary

Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong.

See More

Key Turning Points

2nd Resistance Point 28.90
1st Resistance Point 28.59
Last Price 28.29
1st Support Level 27.89
2nd Support Level 27.50

See More

52-Week High 32.55
Last Price 28.29
Fibonacci 61.8% 26.41
Fibonacci 50% 24.51
Fibonacci 38.2% 22.61
52-Week Low 16.47

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar